The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca
Research Funding - AstraZeneca; Chugai Pharma (Inst)
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); BMG Inc (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb KK (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Kazuko Sakai
Honoraria - Chugai Pharma; Hitachi; Life Technologies; Takeda; YODOSHA
 
Toshihiro Misumi
No Relationships to Disclose
 
Hiroaki Akamatsu
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst)
 
Yasuo Iwamoto
No Relationships to Disclose
 
Noriaki Sakakura
No Relationships to Disclose
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Yasuhisa Ohde
No Relationships to Disclose
 
Hidetoshi Hayashi
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Kyoichi Okishio
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Nippon Kayaku; Takeda
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Ichiro Yoshino
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Care Net; Chugai Pharma; Covidien; CSL Behring; Daiichi Sankyo Pharmaceutical; Japan Blood Products Organization; Johnson & Johnson; Lilly O.; MSD; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Johnson & Johnson; Medicaroid; Medtronic
Research Funding - Daiichi Sankyo Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Jiro Okami
No Relationships to Disclose
 
Kazuhisa Takahashi
Honoraria - Amgen; AstraZeneca; Bristol-Myers K. K.; Chugai Pharma; DAIICHI SANKYO Co., LTD.; Eisai; Kyorin; Lilly Japan; MSD K. K.; Nippon Boehringer Ingelheim; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Sawai Pharmaceutical Co; Shionogi; Taiho Pharmaceutical; Takeda; Viatris
Speakers' Bureau - Chugai Pharma; Kyorin; Novartis
Research Funding - AstraZeneca; Bayer Yakuhin; Bristol-Myers K. K.; Chugai Pharma; Janssen; Janssen; MSD K. K.; Ono Pharmaceutical
 
Norihiko Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Johnson & Johnson; Lilly Japan; Medtronic; MSD; Nihon Medi-Physics; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Fujifilm (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Tetsuya Mitsudomi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ethicon; Guardant Health; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermofisher Scientific Biomarkers
Consulting or Advisory Role - Amgen; AstraZeneca; MSD Oncology; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Hirohito Tada
Honoraria - Chugai Pharma
 
Kazuhiko Nakagawa
Honoraria - Amgen; AstraZeneca Japan; Bayer Yakuhin; Bristol Myers Squibb Company; Chugai Pharma; CMIC; CMIC Co., Ltd.; Daiichi Sankyo Co., Ltd.; Incyte; Janssen; Japan Clinical Research Operations; Life Technologies; Lilly Japan; Medical Mobile Communications; Merck; MSD K.K; Neo Communication; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taiyo Pharma; Takeda; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Research Operations (Inst); Kobayashi Pharmaceutical (Inst); Labcorp Drug Development (Inst); Lilly Japan (Inst); Mebix (Inst); Medical Research Support Y.K. (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); Shionogi (Inst); SRL Diagnostics (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo Co., Ltd. (Inst)
 
Kazuto Nishio
Speakers' Bureau - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; DAIICHI SANKYO; Fujirebio; Guardant Health; Janssen; Lilly Japan; Merck; MSD K.K.; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; SymBio Pharmaceuticals; Takeda; Yakult Honsha
Research Funding - Hitachi Chemical; Lilly Japan; Nichirei; Nippon Boehringer Ingelheim; Osaka Minami Hospital; Otsuka; SYSMEX; West Japan Oncology Group